Wuling Zhu

651 total citations
38 papers, 498 citations indexed

About

Wuling Zhu is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Wuling Zhu has authored 38 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 17 papers in Molecular Biology and 15 papers in Immunology. Recurrent topics in Wuling Zhu's work include CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (12 papers) and Angiogenesis and VEGF in Cancer (7 papers). Wuling Zhu is often cited by papers focused on CAR-T cell therapy research (12 papers), Immune Cell Function and Interaction (12 papers) and Angiogenesis and VEGF in Cancer (7 papers). Wuling Zhu collaborates with scholars based in China. Wuling Zhu's co-authors include Huiyong Zhang, Lingtong Zhi, Changjiang Guo, Zhiyuan Niu, Han Chen, Mingfeng Li, Dongliang Liu, Meichen Yin, Ping Lu and Wei Chun Chang and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and Biochemical and Biophysical Research Communications.

In The Last Decade

Wuling Zhu

35 papers receiving 493 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wuling Zhu China 11 279 266 179 39 37 38 498
Shimrit Mayer Israel 8 187 0.7× 120 0.5× 176 1.0× 70 1.8× 35 0.9× 8 362
Jane Antony United States 10 185 0.7× 165 0.6× 207 1.2× 79 2.0× 18 0.5× 16 448
Franziska Lang Germany 9 212 0.8× 274 1.0× 365 2.0× 47 1.2× 51 1.4× 16 553
Judy P. Doherty Australia 7 199 0.7× 155 0.6× 182 1.0× 132 3.4× 26 0.7× 7 466
Zhenzhen Zhou China 11 128 0.5× 89 0.3× 204 1.1× 64 1.6× 4 0.1× 18 373
Marko Roblek Germany 11 223 0.8× 213 0.8× 227 1.3× 75 1.9× 26 0.7× 17 524
Elizabeth A. Kingsley Australia 13 131 0.5× 54 0.2× 234 1.3× 66 1.7× 18 0.5× 17 482
Christina Delgado United States 11 168 0.6× 269 1.0× 210 1.2× 29 0.7× 27 0.7× 17 490
Matthew Genet United States 12 133 0.5× 102 0.4× 240 1.3× 100 2.6× 38 1.0× 20 498
Ryou Takahashi Japan 6 229 0.8× 41 0.2× 300 1.7× 128 3.3× 42 1.1× 10 525

Countries citing papers authored by Wuling Zhu

Since Specialization
Citations

This map shows the geographic impact of Wuling Zhu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wuling Zhu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wuling Zhu more than expected).

Fields of papers citing papers by Wuling Zhu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wuling Zhu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wuling Zhu. The network helps show where Wuling Zhu may publish in the future.

Co-authorship network of co-authors of Wuling Zhu

This figure shows the co-authorship network connecting the top 25 collaborators of Wuling Zhu. A scholar is included among the top collaborators of Wuling Zhu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wuling Zhu. Wuling Zhu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhi, Lingtong, Zikang Zhang, Qing Gao, et al.. (2025). CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models. BMC Cancer. 25(1). 337–337. 5 indexed citations
2.
Sun, Yang, et al.. (2025). A membrane-bound IL-2 promotes CAR-NK cell proliferation, anti-apoptosis and anti-tumor activity. Biochemical and Biophysical Research Communications. 781. 152495–152495.
3.
Niu, Zhiyuan, Mengjun Wang, Bingqian Xu, et al.. (2024). Challenges in the Development of NK-92 Cells as an Effective Universal Off-the-Shelf Cellular Therapeutic. The Journal of Immunology. 213(9). 1318–1328.
4.
Meng, Dong, Xiang Wang, Lingtong Zhi, et al.. (2024). A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells. Biochemical and Biophysical Research Communications. 710. 149918–149918. 5 indexed citations
5.
Guo, Changjiang, Han Chen, Jie Yu, et al.. (2023). Engagement of an optimized lentiviral vector enhances the expression and cytotoxicity of CAR in human NK cells. Molecular Immunology. 155. 91–99. 7 indexed citations
6.
Li, Xiaojuan, Dong Meng, Xiang Wang, et al.. (2023). The SpyCatcher-SpyTag interaction mediates tunable anti-tumor cytotoxicity of NK cells. Molecular Immunology. 165. 11–18. 7 indexed citations
7.
Zhi, Lingtong, Meichen Yin, Xin Su, et al.. (2022). A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell. Biochemical and Biophysical Research Communications. 600. 94–100. 3 indexed citations
8.
Zhi, Lingtong, Xin Su, Meichen Yin, et al.. (2021). Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges. Cellular Immunology. 369. 104436–104436. 8 indexed citations
9.
Niu, Zhiyuan, et al.. (2020). Explore the activation efficiency of different ligand carriers on synNotch-based contact-dependent activation system. Turkish Journal of Biochemistry. 45(6). 817–823. 2 indexed citations
10.
Zhang, Huiyong, Liang Chen, Xiaoyin Wang, et al.. (2020). VEGF165b and its mutant demonstrate immunomodulatory, not merely anti-angiogenic functions, in tumor-bearing mice. Molecular Immunology. 122. 132–140. 4 indexed citations
11.
Guo, Changjiang, Han Chen, Huiyong Zhang, et al.. (2020). A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis. Molecular Immunology. 122. 200–206. 85 indexed citations
12.
Wang, Xiaoyin, Liang Chen, Changjiang Guo, et al.. (2020). VEGF165b augments NK92 cytolytic activity against human K562 leukemia cells by upregulating the levels of perforin and granzyme B via the VEGR1-PLC pathway. Molecular Immunology. 128. 41–46. 2 indexed citations
13.
Guo, Changjiang, Xiaoyin Wang, Huiyong Zhang, et al.. (2019). Structure-based rational design of a novel chimeric PD1-NKG2D receptor for natural killer cells. Molecular Immunology. 114. 108–113. 36 indexed citations
14.
Zhang, Huiyong, et al.. (2019). Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 37(15). 2090–2098. 9 indexed citations
15.
Zhang, Huiyong, et al.. (2018). VEGF165b mutant with a prolonged half-life and enhanced anti-tumor potency in a mouse model. Journal of Biotechnology. 284. 84–90. 6 indexed citations
16.
Wang, Xiaoyin, et al.. (2017). [Over-expressed HER2 enhances proliferation, migration and invasion of melanoma B16 cells].. PubMed. 33(8). 1067–1072. 1 indexed citations
17.
Wang, Yan, Liyun Gao, Ming Hong, Peng Zhang, & Wuling Zhu. (2016). Polaribacter marinaquae sp. nov., isolated from seawater. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY. 66(11). 4594–4599. 10 indexed citations
18.
Zhang, Huiyong, et al.. (2015). Overexpression of VEGF183 promotes murine breast cancer cell proliferation in vitro and induces dilated intratumoral microvessels. Tumor Biology. 36(5). 3871–3880. 2 indexed citations
19.
Zhang, Huiyong, et al.. (2013). Generation of a Chimeric Plasmin-resistant VEGF165/VEGF183 (132-158) Protein and its Comparative Activity. Protein and Peptide Letters. 20(8). 947–954. 2 indexed citations
20.
Zhu, Wuling, et al.. (2008). Messenger RNA expression of translationally controlled tumor protein (TCTP) in liver regeneration and cancer.. PubMed. 28(3A). 1575–80. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shimrit Mayer Breakdown of academic impact, for papers by Jane Antony Breakdown of academic impact, for papers by Franziska Lang Breakdown of academic impact, for papers by Judy P. Doherty Breakdown of academic impact, for papers by Zhenzhen Zhou Breakdown of academic impact, for papers by Marko Roblek Breakdown of academic impact, for papers by Elizabeth A. Kingsley Breakdown of academic impact, for papers by Christina Delgado Breakdown of academic impact, for papers by Matthew Genet Breakdown of academic impact, for papers by Ryou Takahashi
Rankless by CCL
2026